News
FDA expands use of kidney cancer drug developed from UTSW research
Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved by the Food and Drug Administration to treat some patients with earlier stage kidney cancers in combination with an immunotherapy drug.
Antibody may improve treatment response in lung cancer
An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small cell lung cancer (NSCLC), even those resistant to a targeted therapy, a study led by UT Southwestern Medical Center researchers showed.
Ovarian cancer cells use stress hormone signaling to shut down immune system
When activated in ovarian cancer cells, the receptor for the body’s primary stress hormone alters the tumor environment in ways that blunt immune response, according to new research led by UT Southwestern Medical Center.
Human cells can exchange genomic DNA that alters cell behavior
Scientists at Children’s Medical Center Research Institute at UT Southwestern (CRI) have discovered that large pieces of DNA can transfer directly between human cells, and the DNA can persist and change how the recipient cell functions.
Protein coordinates responses to environmental stress
UT Southwestern Medical Center researchers have discovered a key molecular mechanism that allows animals to adapt to changing environmental conditions without altering their genes – an ability known as phenotypic plasticity.